Literature DB >> 11072263

Neurobehavioral and neuropsychiatric symptoms in Alzheimer's disease: characteristics and treatment.

J A Chung1, J L Cummings.   

Abstract

Neuropsychiatric symptoms are common in Alzheimer's disease. Personality changes, mood disturbance, and psychosis are frequently seen and may coexist in the same patient. Neuropsychiatric symptoms may signal the onset of disease and often fluctuate and recur. These symptoms are associated with a more rapid cognitive and functional decline that can lead to institutionalization. Cholinergic therapy, disease-modifying therapy, and psychotropic medications can improve these symptoms.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11072263     DOI： 10.1016/s0733-8619(05)70228-0

Source DB:  PubMed          Journal:  Neurol Clin        ISSN： 0733-8619            Impact factor:   3.806


  42 in total

Review 1.  APP transgenic mice for modelling behavioural and psychological symptoms of dementia (BPSD).

Authors:  R Lalonde; K Fukuchi; C Strazielle
Journal:  Neurosci Biobehav Rev       Date:  2012-02-21       Impact factor: 8.989

2.  Postoperative adverse outcomes in surgical patients with dementia: a retrospective cohort study.

Authors:  Chaur-Jong Hu; Chien-Chang Liao; Chuen-Chau Chang; Chih-Hsiung Wu; Ta-Liang Chen
Journal:  World J Surg       Date:  2012-09       Impact factor: 3.352

Review 3.  Alzheimer's disease and mild cognitive impairment.

Authors:  Brendan J Kelley; Ronald C Petersen
Journal:  Neurol Clin       Date:  2007-08       Impact factor: 3.806

4.  Progression of cognitive, functional, and neuropsychiatric symptom domains in a population cohort with Alzheimer dementia: the Cache County Dementia Progression study.

Authors:  JoAnn T Tschanz; Chris D Corcoran; Sarah Schwartz; Katherine Treiber; Robert C Green; Maria C Norton; Michelle M Mielke; Kathleen Piercy; Martin Steinberg; Peter V Rabins; Jeanne-Marie Leoutsakos; Kathleen A Welsh-Bohmer; John C S Breitner; Constantine G Lyketsos
Journal:  Am J Geriatr Psychiatry       Date:  2011-06       Impact factor: 4.105

5.  Optogenetic stimulation of dentate gyrus engrams restores memory in Alzheimer's disease mice.

Authors:  Jennifer N Perusini; Stephanie A Cajigas; Omid Cohensedgh; Sean C Lim; Ina P Pavlova; Zoe R Donaldson; Christine A Denny
Journal:  Hippocampus       Date:  2017-07-20       Impact factor: 3.899

6.  A ketone ester diet exhibits anxiolytic and cognition-sparing properties, and lessens amyloid and tau pathologies in a mouse model of Alzheimer's disease.

Authors:  Yoshihiro Kashiwaya; Christian Bergman; Jong-Hwan Lee; Ruiqian Wan; M Todd King; Mohamed R Mughal; Eitan Okun; Kieran Clarke; Mark P Mattson; Richard L Veech
Journal:  Neurobiol Aging       Date:  2012-12-29       Impact factor: 4.673

7.  Loss of prion protein leads to age-dependent behavioral abnormalities and changes in cytoskeletal protein expression.

Authors:  Matthias Schmitz; Catharina Greis; Philipp Ottis; Christopher J Silva; Walter J Schulz-Schaeffer; Arne Wrede; Katharina Koppe; Bruce Onisko; Jesús R Requena; Nambirajan Govindarajan; Carsten Korth; Andre Fischer; Inga Zerr
Journal:  Mol Neurobiol       Date:  2014-03-07       Impact factor: 5.590

8.  A new tacrine-melatonin hybrid reduces amyloid burden and behavioral deficits in a mouse model of Alzheimer's disease.

Authors:  Carlos Spuch; Desiree Antequera; M Isabel Fernandez-Bachiller; M Isabel Rodríguez-Franco; Eva Carro
Journal:  Neurotox Res       Date:  2009-09-23       Impact factor: 3.911

9.  Vitamin C deficiency in the brain impairs cognition, increases amyloid accumulation and deposition, and oxidative stress in APP/PSEN1 and normally aging mice.

Authors:  Shilpy Dixit; Alexandra Bernardo; Jennifer Michelle Walker; John Andrew Kennard; Grace Youngeun Kim; Eric Sean Kessler; Fiona Edith Harrison
Journal:  ACS Chem Neurosci       Date:  2015-02-12       Impact factor: 4.418

10.  Chronic cannabidiol treatment improves social and object recognition in double transgenic APPswe/PS1∆E9 mice.

Authors:  David Cheng; Jac Kee Low; Warren Logge; Brett Garner; Tim Karl
Journal:  Psychopharmacology (Berl)       Date:  2014-03-01       Impact factor: 4.530
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.